TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00585780

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prazosin Tablet
Description: Target medication dosing was three times/day (t.i.d. dosing) with 5 mg in the morning, 5 mg in the afternoon and 6 mg at night reached at the end of the 2-week period, and maintained at this or their highest tolerated dose until week 11, followed by a 5-day taper in week 12, as in previous research.The titration schedule was as follows: 1 mg dose at bedtime for 2 nights, followed by a 1mg dose morning and night (8 AM/8 PM) on day 3, then 2 mg dose t.i.d., on days 4-6, 3 mg dose (2 pills each) morning and afternoon, and 4 mg dose (2 pills) at night for days 7-9, increased to 4 mg dosing t.i.d. on days 10-13, and from day 14 through week 11, 5 mg (1 pill) each in the morning and afternoon, and 6 mg for the night (2 pills) dose. This was followed by a 5-day taper in week 12. Patients were initiated on study medication upon presenting with a negative breathalyzer without any minimum pre-treatment alcohol abstinence period prior to medication initiation.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prazosin Tablet
Description: Target medication dosing was three times/day (t.i.d. dosing) with 5 mg in the morning, 5 mg in the afternoon and 6 mg at night reached at the end of the 2-week period, and maintained at this or their highest tolerated dose until week 11, followed by a 5-day taper in week 12, as in previous research.The titration schedule was as follows: 1 mg dose at bedtime for 2 nights, followed by a 1mg dose morning and night (8 AM/8 PM) on day 3, then 2 mg dose t.i.d., on days 4-6, 3 mg dose (2 pills each) morning and afternoon, and 4 mg dose (2 pills) at night for days 7-9, increased to 4 mg dosing t.i.d. on days 10-13, and from day 14 through week 11, 5 mg (1 pill) each in the morning and afternoon, and 6 mg for the night (2 pills) dose. This was followed by a 5-day taper in week 12. Patients were initiated on study medication upon presenting with a negative breathalyzer without any minimum pre-treatment alcohol abstinence period prior to medication initiation.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Tablet
Description: Placebo tablets identical in appearance and dosing schedule as the active study medication was utilized

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Tablet
Description: Placebo tablets identical in appearance and dosing schedule as the active study medication was utilized
Study: NCT02234466

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oral dexamethasone
Description: Patients will received their study drug ( or placebo) 2 hours pre-induction. Allowing for the shifting schedules of the OR with the possibility of the previous case finishing early or late, the allowable range is 90-200 minutes pre-induction.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ondansetron
Description: Patients in both groups will receive 6mg IV ondansetron at time of skin closure as their standardized prophylaxis for postoperative nausea and vomiting.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ondansetron
Description: Patients in both groups will receive 6mg IV ondansetron at time of skin closure as their standardized prophylaxis for postoperative nausea and vomiting.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Gelatin capsule
Description: Gelatin capsule enclosing either dexamethasone tabs or second gelatin capsule

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Gelatin capsule
Description: Gelatin capsule enclosing either dexamethasone tabs or second gelatin capsule
Study: NCT02199548

Intervention type: OTHER
Intervention: Interview
Description: This study involves teen participants taking part in one private interview with the study team. Interviews last less than one hour and are scheduled at the participant's convenience. Interviews will be audio/digital recorded. Participants may answer any or all of the questions.
Study: NCT03920007

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ATSN-101
Description: Pharmaceutical form:Solution for intraocular administration Route of administration: Subretinal injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ATSN-101 Diluent Solution
Description: Pharmaceutical form:Solution for parenteral use Route of administration: Subretinal injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Pharmaceutical form:Tablet Route of administration: Oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Triamcinalone Acetonide
Description: Pharmaceutical form:Suspension Route of administration: Peri-ocular injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 1% Prednisolone
Description: Pharmaceutical form:Suspension Route of administration: Drops

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trimethoprim/polymyxin B
Description: Pharmaceutical form:Solution Route of administration: Topical
Study: NCT02158832

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Acupuncture + Electrical Stimulation
Description: 2 acupuncture needles are inserted into the upper back. 10Hz, 0.5ms biphasic square wave electrical pulses are applied to needles x20 mins. Current \>sensation threshold \& maintained at a level that is comfortable/painless \& does not elicit skeletal muscle contractions (\~5mA, \<10mA).~Needle locations are in the vicinity of nerves that supply the affected upper limb:~EX-B1': Affected hemisphere, 1.5cm lateral to C5 spinous process. Insertion angle: shallow, 'inferior-lateral', \~15⁰ perpendicular to the skin, \~15⁰ lateral to the midline. Depth: \~1.5 cm (secure anchorage).~EX-HN15': Affected hemisphere, 1.5cm lateral to the C7 spinous process. Insertion angle: shallow, 'inferior-medial' \~15⁰ perpendicular to the skin, \~15⁰ medial. Depth: \~1.5 cm (secure anchorage).
Study: NCT00958178

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxygen
Description: Experimental: Low flow Oxygen for 30 seconds then high flow for 3.5 minutes. Active comparator: High flow Oxygen for 4 minutes.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxygen
Description: Experimental: Low flow Oxygen for 30 seconds then high flow for 3.5 minutes. Active comparator: High flow Oxygen for 4 minutes.
Study: NCT02480764

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azilsartan medoxomil
Description: Azilsartan medoxomil tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azilsartan medoxomil
Description: Azilsartan medoxomil tablets

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Valsartan
Description: Valsartan 80 mg capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azilsartan medoxomil Placebo
Description: Azilsartan medoxomil placebo-matching tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azilsartan medoxomil Placebo
Description: Azilsartan medoxomil placebo-matching tablets

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Azilsartan medoxomil Placebo
Description: Azilsartan medoxomil placebo-matching tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Valsartan Placebo
Description: Valsartan placebo-matching capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Valsartan Placebo
Description: Valsartan placebo-matching capsules

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Valsartan Placebo
Description: Valsartan placebo-matching capsules
Study: NCT00301769

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SJG-136
Description: Given IV
Study: NCT01938586

Intervention type: OTHER
Intervention: Steri-Strip

Intervention type: OTHER
Intervention: Superficial sutures
Study: NCT03030196

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Denosumab
Description: NaCl 0.9% injection is used as placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Denosumab
Description: NaCl 0.9% injection is used as placebo
Study: NCT03909516

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: iovera°
Description: The iovera° device will be prepared by the trained Anesthesiologist User Guide. If at any time the device does not perform as expected the Investigator and Anesthesiologist will follow procedures as outlined in the User Guide. Start and end time will be recorded. Once localized anesthesia of the block area is achieved, the Anesthesiolgist, or designee, will complete the iovera° treatment. Upon completion of block, The Anesthesiologist or designee will assess the treatment areas for adverse events. Adductor Canal Block required, the formulation, or cocktail, of medications used are to be recorded in the medical record. Start and end time will be recorded.~Local Infiltration Analgesia - 20cc 0.5% ropivicaine only
Study: NCT00515203

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Starting dose of 1.0 ug/kg. Dose adjustments are made throughout the study based on individual platelet counts.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMG 531
Description: Starting dose of 1.0 ug/kg. Dose adjustments are made throughout the study based on individual platelet counts.
Study: NCT00762307

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Zeltiq Dermal Cooling Device
Description: Noninvasive cooling is applied to the treatment area with a defined cooling rate and duration.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Zeltiq Dermal Cooling Device
Description: Noninvasive cooling is applied to the treatment area with a defined cooling rate and duration.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Zeltiq Dermal Cooling Device
Description: Noninvasive cooling is applied to the treatment area with a defined cooling rate and duration.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Zeltiq Dermal Cooling Device
Description: Noninvasive cooling is applied to the treatment area with a defined cooling rate and duration.
Study: NCT04323202

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Post Fine-cut CT: 4 doses of pembrolizumab (200mg) IV q 3 weeks. Post standard resection and reconstruction: 1 year of pembrolizumab (200mg) q 3 weeks (another 13 doses, thus 17 doses total)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tissue collection
Description: Non-marginal tissue as well as pre-op biopsy tissue to be stored
Study: NCT02126306

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Beta Glucosylceramide
Description: Beta Glucosylceramide

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: normal saline
Study: NCT01992055

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Goal Management Training
Description: Participants will be randomly assigned to the GMT Treatment. The GMT cognitive rehabilitation intervention program will be administered in group format, consisting of 8 sessions, including structured psychoeducation, relaxation training, and stepwise learning of GMT.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Education & relaxation training
Description: The Education \& Relaxation Training Control Group program will also be administered in group format, consisting of two sessions, including structured psychoeducation and relaxation training. Participants assigned to the Control condition will be offered the opportunity to complete the full GMT program following the completion of the study.
Study: NCT02467621

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pantoprazole
Description: 40 mg x 1 daily intravenously from ICU admission to ICU discharge

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Saline (0.9%)
Description: 10 ml of isotonic saline x 1 daily intravenously from ICU admission to ICU discharge
Study: NCT02612636

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: ear plug
Description: The patients will receive the intervention (ear plug) in the third night (N3) from 9 pm to 6 am.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: eye mask
Description: The patients will receive the intervention (eye mask) in the second night (N2) from 9 pm to 6 am.
Study: NCT02283775

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isatuximab SAR650984
Description: Pharmaceutical form:solution for infusion Route of administration: intravenous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pomalidomide
Description: Pharmaceutical form:capsules Route of administration: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Pharmaceutical form:tablets or solution for infusion Route of administration: oral or intravenous
Study: NCT01076972

Intervention type: DRUG
Intervention: Lopinavir/ritonavir (Kaletra)
Description: Lopinavir/ritonavir evaluated separately in patients who were naive to previous antiretroviral treatment and those who were not.
Study: NCT01051193

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxcarbazepine
Study: NCT00824265

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OFC Infusion
Description: Ofatumumab Cycle 1-Day 1 300mg, Cycle 1-Day 8 1000mg, then Cycles 2-6 Day 1 1000mg every 28 days, Fludarabine 25mg/m2 Days 1-3 every 28 days for 6 cycles, Cyclophosphamide 250 mg/m2 Days 1-3 every 28 days for 6 cycles

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: FC infusion
Description: Fludarabine 25mg/m2 Days 1-3 every 28 days for 6 cycles, Cyclophosphamide 250mg/m2 Days 1-3 every 28 days for 6 cycles
Study: NCT02125266

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: V404
Description: Sustained Release

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: V404
Description: Sustained Release
Study: NCT04149964

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acetaminophen 325 mg Oral Tablet
Description: Standard of Care Acetaminophen 325 mg every 6 hours as needed for pain

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetaminophen 650 mg Oral Tablet
Description: Acetaminophen 650 mg scheduled every 6 hours round the clock for pain

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OxyCODONE 5 mg Oral Tablet
Description: Oxycodone 5 mg every 4 hours as needed for breakthrough pain

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acetaminophen/Hydrocodone 325 mg/7.5 mg oral tablet
Description: Acetaminophen 325 mg/ Hydrocodone 7.5 mg oral tablet every 4 hours as needed for breakthrough pain
Study: NCT03437083

Intervention type: DRUG
Intervention: Eribulin mesylate
Description: intravenous infusion
Study: NCT04790448

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: Route of administration: Intravenous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: Route of administration: Intravenous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vemurafenib
Description: Route of administration: Oral
Study: NCT01624220

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Spinal SBRT (Standard Dose)
Description: Group 1 and 2: Standard doses of radiation therapy to the normal esophagus while treating the tumor. Up to 2 groups of 10 participants enrolled.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Spinal SBRT (Higher Dose)
Description: Group 3 and 4: Higher dose of radiation to esophagus than group before it, if no intolerable side effects were seen. 2 groups of 10 participants enrolled in the second part of study. Only participants who will receive a single spinal SBRT treatment are eligible for second part of study.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Gold Seed Implantation
Description: 4 gold seeds implanted into bones of spine: 2 gold seeds above and 2 gold seeds below the area of tumor to be treated.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Gold Seed Implantation
Description: 4 gold seeds implanted into bones of spine: 2 gold seeds above and 2 gold seeds below the area of tumor to be treated.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Questionnaires
Description: Completion of questionnaire before radiation treatment starts, and 1 time a week for the next 4 weeks. It should take about 10 minutes to complete.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Questionnaires
Description: Completion of questionnaire before radiation treatment starts, and 1 time a week for the next 4 weeks. It should take about 10 minutes to complete.
Study: NCT01432977

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: paracetamol /droperidol

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paracetamol / ondansetron
Study: NCT01722448

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Choline
Description: 4 capsules with 480 mg choline per day

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT01230580

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Protease Inhibitor
Description: Switch to a regimen comprising a single ritonavir-boosted Protease Inhibitor

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard-of-care Antiretroviral therapy
Description: Regimen should consist of 3 drugs: 2 nucleoside reverse transcriptase inhibitors with either a non-nucleoside reverse transcriptase inhibitor or a protease inhibitor
Study: NCT01305070

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Admiral Xtreme
Description: For balloon angioplasty of in-stent restenosis in the superficial femoral artery

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: In.Pact Admiral
Description: For balloon angioplasty of in-stent restenosis in the superficial femoral artery
Study: NCT02661529

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Transesophageal Echocardiogram (TEE)
Description: Transesophageal echocardiography (TEE) is a test that produces pictures of the heart. TEE uses high-frequency sound waves (ultrasound) to make detailed pictures of the heart and the arteries that lead to and from it. Unlike a standard echocardiogram, the echo transducer that produces the sound waves for TEE is attached to a thin tube that passes through the mouth, down the throat and into the esophagus. Because the esophagus is so close to the upper chambers of the heart, very clear images of those heart structures and valves can be obtained.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Transthoracic Echocardiogram (TTE)
Description: An echocardiogram is a type of ultrasound test that uses high-pitched sound waves that are sent through a device called a transducer. The device picks up echoes of the sound waves as they bounce off the different parts of the heart. These echoes are turned into moving pictures of the heart that can be seen on a video screen.~Transthoracic echocardiogram (TTE) is the most common type of echocardiogram. Views of the heart are obtained by moving the transducer to different locations on the chest or abdominal wall.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Saline/Air Mixture
Description: The Saline/Air mixture consists of 10 milliliters of sterile saline and 0.5 milliliters of air agitated together in a syringe prior to injection.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Saline/Air Mixture
Description: The Saline/Air mixture consists of 10 milliliters of sterile saline and 0.5 milliliters of air agitated together in a syringe prior to injection.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Saline/Blood Mixture
Description: The Saline/Blood mixture consists of 9 milliliters of sterile saline and 0.5 - 1.0 milliliters of blood agitated together in a syringe prior to injection.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Saline/Blood Mixture
Description: The Saline/Blood mixture consists of 9 milliliters of sterile saline and 0.5 - 1.0 milliliters of blood agitated together in a syringe prior to injection.
Study: NCT04360993

Intervention type: RADIATION
Intervention: Radiotherapy
Description: Patients have received radiotherapy as a treatment modality for Head and neck cancer
Study: NCT03832400

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MET-2
Description: MET-2 is a defined consortium of human commensal bacteria derived from a healthy donor, which has the full metabolic functional capacity of fecal microbiota.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MET-2
Description: MET-2 is a defined consortium of human commensal bacteria derived from a healthy donor, which has the full metabolic functional capacity of fecal microbiota.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral capsule
Description: Placebo oral capsule which is identical to the MET-2 capsules.
Study: NCT01740609

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PF-06342674 Dose A
Description: Single SC Dose

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PF-06342674 Dose B
Description: Single SC Dose

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PF-06342674 Dose C
Description: Single SC Dose

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PF-06342674 Dose D
Description: Single SC Dose

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PF-06342674 Dose E
Description: Single SC Dose

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PF-06342674 Dose F
Description: Single IV Dose

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PF-06342674 Dose G
Description: Single SC Dose

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PF-06342674 Dose H
Description: Single IV Dose

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PF-06342674 Dose I
Description: Single SC Dose

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PF-06342674 Dose J
Description: Single IV Dose
Study: NCT03605043

Intervention type: OTHER
Intervention: Blood pressure management in the HIV program
Description: Integrated care for hypertension and HIV in the HIV program
Study: NCT04598984

Intervention type: DIAGNOSTIC_TEST
Intervention: serum adipokines
Description: Level of serum adipokines will be measured with flow cytometry

Intervention type: DIAGNOSTIC_TEST
Intervention: serum adipokines
Description: Level of serum adipokines will be measured with flow cytometry
Study: NCT03392909

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gentamicin
Description: Short-term intravenous gentamicin therapy should have the advantage of treating all of the patient's multiple skin wounds simultaneously. Six patients (three adults and 3 children) will receive intravenous gentamicin (7.5 mgs/kg) daily for 14 days and then stopped. Three adult patients will receive intravenous gentamicin (7.5mg/kg) biweekly for three months and then stopped.
Study: NCT01504737

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aerobic Exercise Training
Description: 12 weeks of endurance training, 40 minutes, 3 times per week on ergometer bicycle.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Physical Activity Recommendations
Description: Written and verbal information on minimal level of physical activity recommended.